Pluri Inc.

Equities

PLUR

US72942G2030

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.357 ^USD	+9.33%		+2.04%	+15.55%

Apr. 08	Sector Update: Health Care Stocks Decline Late Afternoon	MT
Apr. 08	Sector Update: Health Care	MT

Pluri Inc. announced that it has received $8.469323 million in funding

December 29, 2022

On December 30, 2022, Pluristem Therapeutics, Inc closed the transaction. The company amended the terms of the transaction. The company has received $8,469,323 pursuant to exemption provided under Regulation D form 14 investors.

Latest news about Pluri Inc.

Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 08	MT
Sector Update: Health Care	Apr. 08	MT
Pluri Receives US Patent for Immune Cell Expansion	Apr. 08	MT
Pluri Inc. Unveils A Novel Method for Expansion of Immune Cells Using Proprietary Technology	Apr. 08	CI
Pluri Selected as Cdmo by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing	Mar. 14	CI
Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation	Mar. 11	CI
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board	Mar. 06	CI
Pluri Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 12	CI
Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis	Jan. 23	CI
Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division	Jan. 08	CI
Pluri Inc. Launches New Business Division Offering Cell Therapy Manufacturing Services as Contract Development and Manufacturing Organization: PluriCDMO	Jan. 08	CI
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction	Dec. 21	CI
Pluri Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 13	CI
Pluri Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-12	CI
Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation	23-08-16	CI
Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors	23-07-13	CI
Pluri Signs Contract With US Institute of Allergy and Infectious Diseases to Develop Radiation Syndrome Treatment	23-07-11	MT
Pluri Inc. Signs A Three Year $4.2 Million Contract with the U.S. National Institute of Allergy and Infectious Diseases	23-07-11	CI
Pluri Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-09	CI
Pluri Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-13	CI
Pluri Inc. announced that it has received $8.469323 million in funding	22-12-29	CI
Pluri Inc. announced that it expects to receive $8.170972 million in funding	22-12-12	CI
Pluri Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-10	CI
Pluri Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-21	CI
Pluri Inc.(NasdaqGM:PLUR) dropped from S&P Global BMI Index	22-09-19	CI

Chart Pluri Inc.

Duration

Period

More charts

Company Profile

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q3 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
PLURI INC.	+15.55%	27.91M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

Pluri Inc.

Equities

PLUR

US72942G2030

Biotechnology & Medical Research

Pluri Inc. announced that it has received $8.469323 million in funding

Latest news about Pluri Inc.

Chart Pluri Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research